Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8913701rdf:typepubmed:Citationlld:pubmed
pubmed-article:8913701lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:8913701lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:8913701lifeskim:mentionsumls-concept:C0030559lld:lifeskim
pubmed-article:8913701lifeskim:mentionsumls-concept:C0007613lld:lifeskim
pubmed-article:8913701lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:8913701lifeskim:mentionsumls-concept:C0002508lld:lifeskim
pubmed-article:8913701lifeskim:mentionsumls-concept:C0025033lld:lifeskim
pubmed-article:8913701lifeskim:mentionsumls-concept:C0061355lld:lifeskim
pubmed-article:8913701lifeskim:mentionsumls-concept:C0086379lld:lifeskim
pubmed-article:8913701lifeskim:mentionsumls-concept:C0234402lld:lifeskim
pubmed-article:8913701pubmed:issue6lld:pubmed
pubmed-article:8913701pubmed:dateCreated1997-2-19lld:pubmed
pubmed-article:8913701pubmed:abstractTextWe have previously shown that in highly enriched rat gastric parietal cells the intestinal peptide hormones oxyntomodulin and glucagon-like peptide-2 (GLP-2) compete for receptor-binding with glucagon-like peptide-1 (GLP-1), a potent cAMP-dependent stimulus of H+ production in vitro. It is, however, unknown whether oxyntomodulin and GLP-2 elicit a biological response by interacting with the GLP-1 receptor. Therefore, we used enriched rat parietal cells to investigate the effects of both hormones on the production of cAMP and H+ ([14C]aminopyrine accumulation). Both parameters were stimulated by oxyntomodulin in a concentration-dependent manner. EC50 values were 6.2.10(-8) and 2.5.10(-7) M oxyntomodulin for stimulation of H+ and cAMP production, respectively. The maximally effective concentrations for stimulation of [14C]aminopyrine accumulation and cAMP production were 1.10(-6) and 1.10(-5) M oxyntomodulin, respectively. At these concentrations oxyntomodulin was nearly as effective as 10(-4) M histamine and equally effective as 10(-8) M GLP-1 (7-36)NH2. In the enriched parietal cell preparation there was no immunocytochemical evidence of contaminating D cells. Accordingly, the responses to oxyntomodulin and GLP-1 (7-36)NH2 were not augmented by incubating the cells in the presence of a polyclonal anti-somatostatin antibody. [14C]Aminopyrine accumulation in response to oxyntomodulin was inhibited by the GLP-1 (7-36)NH2 receptor antagonist, exendin (9-39)NH2, but not by the H2-receptor antagonist, ranitidine. Oxyntomodulin and carbachol acted additively to stimulate [14C]aminopyrine accumulation. GLP-2 (10(-7) to 10(-5)M) was without effect on basal H+ and cAMP production; however, at 10(-5) M GLP-2 markedly inhibited oxyntomodulin-stimulated [14C]aminopyrine accumulation. It is concluded that, by interacting with parietal cell receptors for GLP-1 (7-36)NH2, oxyntomodulin, but not GLP-2, directly stimulates H+ production by activating the adenylate cyclase.lld:pubmed
pubmed-article:8913701pubmed:languageenglld:pubmed
pubmed-article:8913701pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8913701pubmed:citationSubsetIMlld:pubmed
pubmed-article:8913701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8913701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8913701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8913701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8913701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8913701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8913701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8913701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8913701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8913701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8913701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8913701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8913701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8913701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8913701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8913701pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8913701pubmed:statusMEDLINElld:pubmed
pubmed-article:8913701pubmed:issn0012-2823lld:pubmed
pubmed-article:8913701pubmed:authorpubmed-author:ClassenMMlld:pubmed
pubmed-article:8913701pubmed:authorpubmed-author:ScheppWWlld:pubmed
pubmed-article:8913701pubmed:authorpubmed-author:SchmidtlerJJlld:pubmed
pubmed-article:8913701pubmed:authorpubmed-author:DehneKKlld:pubmed
pubmed-article:8913701pubmed:authorpubmed-author:RiedelTTlld:pubmed
pubmed-article:8913701pubmed:authorpubmed-author:SchafferKKlld:pubmed
pubmed-article:8913701pubmed:issnTypePrintlld:pubmed
pubmed-article:8913701pubmed:volume57lld:pubmed
pubmed-article:8913701pubmed:ownerNLMlld:pubmed
pubmed-article:8913701pubmed:authorsCompleteYlld:pubmed
pubmed-article:8913701pubmed:pagination398-405lld:pubmed
pubmed-article:8913701pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:meshHeadingpubmed-meshheading:8913701-...lld:pubmed
pubmed-article:8913701pubmed:articleTitleOxyntomodulin: a cAMP-dependent stimulus of rat parietal cell function via the receptor for glucagon-like peptide-1 (7-36)NH2.lld:pubmed
pubmed-article:8913701pubmed:affiliationDepartment of Internal Medicine II, Technical University of Munich, Germany.lld:pubmed
pubmed-article:8913701pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8913701pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:8913701pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8913701lld:pubmed